07:00 , Jul 24, 2014 |  BC Innovations  |  Cover Story

It is an RNA world

RNA-based molecules have redefined the universe of tractable targets by putting virtually anything that is gene encoded within reach of a disease-modifying agent. This redefinition has launched RNA as the biotech industry's third drug modality. The...
07:00 , Jul 16, 2007 |  BC Week In Review  |  Clinical News

Bevasiranib: Phase III started

OPK (formerly Acuity Pharmaceuticals Inc.) began the international Phase III COBALT trial in 330 patients to compare bevasiranib dosed every 8 and 12 weeks vs. Lucentis dosed every 4 weeks. Genentech Inc....
07:00 , Jun 11, 2007 |  BC Week In Review  |  Company News

Opko, Ophthalmic Technologies Inc. deal

EXEG will acquire the two-thirds of diagnostic company Ophthalmic it does not already own for about $17.6 million in stock. EXEG disclosed that in April, it purchased one-third of Ophthalmic for $5 million in cash...
07:00 , Apr 2, 2007 |  BC Week In Review  |  Company News

Acuity, eXegenics, Froptix Corp. deal

Acuity and Froptix reverse-merged with shell company EXEG to form Opko Corp., which will be located in Miami, Fla. The newco has $16 million in cash from EXEG and a $12 million line of credit...
08:00 , Jan 29, 2007 |  BioCentury  |  Product Development

Optical focus

For years, the ophthalmic space was more or less moribund as far as biotech was concerned, populated mainly by old-line companies peddling old-line treatments. But both the aging of the population and the rise in...
08:00 , Dec 4, 2006 |  BioCentury  |  Tools & Techniques

Systemic RNAi

Even as popular opinion has begun to inch toward "when" rather than "whether" RNA interference will emerge as a viable therapeutic modality, identifying a method for systemic delivery is one obstacle that remains in many...
08:00 , Nov 6, 2006 |  BioCentury  |  Strategy

Sirna or later

Merck & Co. Inc.'s willingness to pay $1.1 billion to acquire Sirna Therapeutics Inc., one of only a few companies to have reached the clinic with a short interfering RNA (siRNA) candidate, provides a real...
08:00 , Oct 30, 2006 |  BC Week In Review  |  Company News

Acuity management update

Acuity Pharmaceuticals Inc., Philadelphia, Penn.   Business: Ophthalmic   Hired: Denis O'Shaughnessy as SVP of clinical development, formerly SVP of clinical development at OSI Pharmaceuticals Inc.'s OSI Eyetech unit   ...
07:00 , Sep 18, 2006 |  BC Week In Review  |  Clinical News

Bevasiranib: Additional Phase II data

In the double-blind, U.S. Phase II C.A.R.E. trial in 129 patients, bevasiranib was safe and well tolerated. Patients received 0.2, 1.5 or 3 mg of intravitreal bevasiranib per eye at the start of the study...
07:00 , Aug 28, 2006 |  BC Week In Review  |  Clinical News

Acuity, Pathogenics preclinical data

In a rabbit model of viral conjunctivitis, animals treated with N-chlorotaurine (NCT) had significantly fewer positive cultures during days 1-14 after injection compared with those treated with a saline control. Also, the NCT group had...